4baseCare and Cellworks (USA) have collaborated to launch TARGT ABSOLUTE PLUS test which is the most comprehensive test with a whole-exome and transcriptome approach to identify DNA and RNA alterations in ~20,000 genes .
The comprehensive analysis provides insights on Somatic (SNVs/InDels, Copy Number Alterations (CNAs), and Gene Fusions/Splice Variants) and Immunotherapy (TMB, MSI, PD-L1) biomarkers along with true Somatic and Germline variants.
In addition to this, Cellworks Bio-Simulation Platform and Computational Omics Biology Model (CBM) is used to predict individual patients’ response to therapies using Therapy Response Index (TRI) within Cellworks Singula, and Cellworks Ventura reports.
The comprehensive tumor profiling approach (using AI/ML Biosimulation Approach) reveals the highest quality molecular blueprint to guide more precise and individualized treatment decisions that are proven to extend overall survival.